Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001847367-26-000024
Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial popul ation ( LINK TO PR ) .
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.91M | $2.07M | — | — |
| Net Income | -$94.88M | -$110.75M | -$93.12M |
Alumis Inc. · CIK 1847367 · Engraved from SEC EDGAR
| -$43.38M |
| EPS Diluted | -$0.73 | -$1.06 | -$1.73 | -$19.76 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alumis reported a net loss of $94.9 million for the quarter ended September 30, 2026, compared to a net loss of $110.8 million for the quarter ended September 30, 2025.¶2
Collaboration revenue was $1.9 million for the quarter ended September 30, 2026, compared to $2.1 million a year earlier, and research and development expenses were $80.8 million, compared to $97.8 million.¶3¶4
The Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its primary and secondary endpoints in the overall trial population.¶1
As of September 30, 2026, Alumis had cash, cash equivalents and marketable securities of $431.3 million, which it expects to fund operations into the fourth quarter of 2027.¶5¶6
Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.¶7